Journey Medical Corporation reported second-quarter revenues of $18.5 million, representing a 23% increase [1].
The growth indicates the company is successfully scaling the launch of Emrosi, a product seeing rapid adoption among healthcare providers and improved insurance coverage.
Company data shows that the number of prescribers for Emrosi rose by over 40% quarter-over-quarter [1]. This increase in adoption coincides with a rise in high-quality formulary coverage, which grew from 34% to 38% [1, 2]. Total sales for Emrosi reached $8.1 million [2].
Financial reports for the period show a discrepancy in total revenue figures. While some reports cite $18.5 million [1], other data lists net revenue for the second quarter of the 2025 fiscal year at $15 million [3]. Similarly, sales for the product, referred to as MROSI in some records, were listed at $2.8 million in the fiscal 2025 report [3].
Executive leadership said that the company expects further financial gains through its pricing and reimbursement strategies. "Our expectation is that we'll continue to gain better ASPs as more reimbursement from our payer strategy gets implemented," Maraoui said [2].
The company's strategy focuses on increasing the average selling price (ASP) by securing more favorable terms from insurance payers. This approach, combined with the expansion of the prescriber base, has contributed to the company achieving positive EBITDA during the period [1].
“Q2 revenues up 23% to $18.5M”
The discrepancy between the $18.5 million and $15 million revenue figures suggests a difference between reporting periods or accounting methods between the current 2026 calendar year and the 2025 fiscal year. However, the consistent trend across sources is the growth of Emrosi, which is shifting from a launch phase to a scaling phase through increased insurance coverage and physician adoption.
